Xeris Biopharma Holdings, Inc. provided revenue guidance for the year 2024. The company anticipates 2024 total revenue to grow from 2023 levels.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.855 USD | +0.27% | -1.61% | -22.13% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.13% | 274M | |
+32.51% | 698B | |
+26.51% | 568B | |
-4.64% | 358B | |
+19.04% | 328B | |
+3.63% | 283B | |
+16.34% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+7.98% | 165B |
- Stock Market
- Equities
- XERS Stock
- News Xeris Biopharma Holdings, Inc.
- Xeris Biopharma Holdings, Inc. Provides Revenue Guidance for the Year 2024